FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) Stock Fundamental Analysis

NASDAQ:FBIOP • US34960Q2084

11.11 USD
0 (0%)
Last: Feb 13, 2026, 08:06 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall FBIOP gets a fundamental rating of 3 out of 10. We evaluated FBIOP against 523 industry peers in the Biotechnology industry. Both the profitability and financial health of FBIOP have multiple concerns. While showing a medium growth rate, FBIOP is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year FBIOP has reported negative net income.
  • In the past year FBIOP has reported a negative cash flow from operations.
  • FBIOP had negative earnings in each of the past 5 years.
  • FBIOP had a negative operating cash flow in each of the past 5 years.
FBIOP Yearly Net Income VS EBIT VS OCF VS FCFFBIOP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

  • FBIOP's Return On Assets of -2.94% is amongst the best of the industry. FBIOP outperforms 86.81% of its industry peers.
  • FBIOP has a better Return On Equity (-9.55%) than 87.95% of its industry peers.
Industry RankSector Rank
ROA -2.94%
ROE -9.55%
ROIC N/A
ROA(3y)-36.39%
ROA(5y)-27.89%
ROE(3y)-252.68%
ROE(5y)-172.79%
ROIC(3y)N/A
ROIC(5y)N/A
FBIOP Yearly ROA, ROE, ROICFBIOP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

1.3 Margins

  • With an excellent Gross Margin value of 71.56%, FBIOP belongs to the best of the industry, outperforming 82.22% of the companies in the same industry.
  • FBIOP's Gross Margin has declined in the last couple of years.
  • FBIOP does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 71.56%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.13%
GM growth 5Y-2.19%
FBIOP Yearly Profit, Operating, Gross MarginsFBIOP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • FBIOP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • FBIOP has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for FBIOP has been increased compared to 5 years ago.
  • The debt/assets ratio for FBIOP is higher compared to a year ago.
FBIOP Yearly Shares OutstandingFBIOP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
FBIOP Yearly Total Debt VS Total AssetsFBIOP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • FBIOP has an Altman-Z score of -4.91. This is a bad value and indicates that FBIOP is not financially healthy and even has some risk of bankruptcy.
  • FBIOP's Altman-Z score of -4.91 is on the low side compared to the rest of the industry. FBIOP is outperformed by 60.99% of its industry peers.
  • FBIOP has a Debt/Equity ratio of 0.86. This is a neutral value indicating FBIOP is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.86, FBIOP is not doing good in the industry: 72.66% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF N/A
Altman-Z -4.91
ROIC/WACCN/A
WACC12.77%
FBIOP Yearly LT Debt VS Equity VS FCFFBIOP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M -150M

2.3 Liquidity

  • A Current Ratio of 2.19 indicates that FBIOP has no problem at all paying its short term obligations.
  • The Current ratio of FBIOP (2.19) is worse than 74.38% of its industry peers.
  • A Quick Ratio of 1.97 indicates that FBIOP should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.97, FBIOP is doing worse than 74.57% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.19
Quick Ratio 1.97
FBIOP Yearly Current Assets VS Current LiabilitesFBIOP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 57.37% over the past year.
  • The Revenue has decreased by -0.32% in the past year.
  • The Revenue has been growing by 9.50% on average over the past years. This is quite good.
EPS 1Y (TTM)57.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.47%
Revenue 1Y (TTM)-0.32%
Revenue growth 3Y-5.71%
Revenue growth 5Y9.5%
Sales Q2Q%20.52%

3.2 Future

  • The Earnings Per Share is expected to grow by 35.19% on average over the next years. This is a very strong growth
  • FBIOP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 64.44% yearly.
EPS Next Y109.83%
EPS Next 2Y41.53%
EPS Next 3Y35.19%
EPS Next 5YN/A
Revenue Next Year24.62%
Revenue Next 2Y36.42%
Revenue Next 3Y35.16%
Revenue Next 5Y64.44%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
FBIOP Yearly Revenue VS EstimatesFBIOP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
FBIOP Yearly EPS VS EstimatesFBIOP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for FBIOP. In the last year negative earnings were reported.
  • A Price/Forward Earnings ratio of 1089.22 indicates a quite expensive valuation of FBIOP.
  • Based on the Price/Forward Earnings ratio, FBIOP is valued cheaply inside the industry as 86.81% of the companies are valued more expensively.
  • FBIOP's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.96.
Industry RankSector Rank
PE N/A
Fwd PE 1089.22
FBIOP Price Earnings VS Forward Price EarningsFBIOP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 200 400 600 800 1K

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FBIOP Per share dataFBIOP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • A more expensive valuation may be justified as FBIOP's earnings are expected to grow with 35.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.53%
EPS Next 3Y35.19%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • FBIOP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

FORTRESS BIOTECH INC - FBIO 9 3/8 PERP

NASDAQ:FBIOP (2/13/2026, 8:06:18 PM)

11.11

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-24
Inst Owners15.2%
Inst Owner ChangeN/A
Ins Owners14.3%
Ins Owner ChangeN/A
Market Cap344.85M
Revenue(TTM)62.30M
Net Income(TTM)-5.34M
Analysts82.5
Price Target42.4 (281.64%)
Short Float %0.08%
Short Ratio0.78
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.22
Dividend Growth(5Y)-17.74%
DP-12.44%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)44.76%
Min EPS beat(2)-36.17%
Max EPS beat(2)125.68%
EPS beat(4)3
Avg EPS beat(4)24.21%
Min EPS beat(4)-36.17%
Max EPS beat(4)125.68%
EPS beat(8)6
Avg EPS beat(8)23.87%
EPS beat(12)7
Avg EPS beat(12)18.85%
EPS beat(16)9
Avg EPS beat(16)-3.2%
Revenue beat(2)1
Avg Revenue beat(2)-3.53%
Min Revenue beat(2)-17.76%
Max Revenue beat(2)10.71%
Revenue beat(4)2
Avg Revenue beat(4)-1.31%
Min Revenue beat(4)-17.76%
Max Revenue beat(4)10.85%
Revenue beat(8)3
Avg Revenue beat(8)-5.02%
Revenue beat(12)5
Avg Revenue beat(12)3.82%
Revenue beat(16)6
Avg Revenue beat(16)-2.87%
PT rev (1m)48.78%
PT rev (3m)44.98%
EPS NQ rev (1m)131.88%
EPS NQ rev (3m)125%
EPS NY rev (1m)150%
EPS NY rev (3m)131.82%
Revenue NQ rev (1m)13.07%
Revenue NQ rev (3m)9.07%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1089.22
P/S 5.54
P/FCF N/A
P/OCF N/A
P/B 6.17
P/tB 12.68
EV/EBITDA N/A
EPS(TTM)-1.62
EYN/A
EPS(NY)0.01
Fwd EY0.09%
FCF(TTM)-2.61
FCFYN/A
OCF(TTM)-2.13
OCFYN/A
SpS2.01
BVpS1.8
TBVpS0.88
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2.94%
ROE -9.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 71.56%
FCFM N/A
ROA(3y)-36.39%
ROA(5y)-27.89%
ROE(3y)-252.68%
ROE(5y)-172.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.13%
GM growth 5Y-2.19%
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.19
Quick Ratio 1.97
Altman-Z -4.91
F-Score4
WACC12.77%
ROIC/WACCN/A
Cap/Depr(3y)152.42%
Cap/Depr(5y)127.86%
Cap/Sales(3y)11.86%
Cap/Sales(5y)9.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.47%
EPS Next Y109.83%
EPS Next 2Y41.53%
EPS Next 3Y35.19%
EPS Next 5YN/A
Revenue 1Y (TTM)-0.32%
Revenue growth 3Y-5.71%
Revenue growth 5Y9.5%
Sales Q2Q%20.52%
Revenue Next Year24.62%
Revenue Next 2Y36.42%
Revenue Next 3Y35.16%
Revenue Next 5Y64.44%
EBIT growth 1Y10.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.86%
EBIT Next 3Y23.67%
EBIT Next 5YN/A
FCF growth 1Y42.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y53.14%
OCF growth 3YN/A
OCF growth 5YN/A

FORTRESS BIOTECH INC - FBIO 9 3/8 PERP / FBIOP FAQ

Can you provide the ChartMill fundamental rating for FORTRESS BIOTECH INC - FBIO 9 3/8 PERP?

ChartMill assigns a fundamental rating of 3 / 10 to FBIOP.


What is the valuation status for FBIOP stock?

ChartMill assigns a valuation rating of 2 / 10 to FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP). This can be considered as Overvalued.


What is the profitability of FBIOP stock?

FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) has a profitability rating of 2 / 10.


What is the earnings growth outlook for FORTRESS BIOTECH INC - FBIO 9 3/8 PERP?

The Earnings per Share (EPS) of FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) is expected to grow by 109.83% in the next year.